Brighter tomorrow.

Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world we’re trying to build by developing our innovative family of simple, easy to use, cost-effective tests.

Our patented technologies use chromosomal structures such as nucleosomes and transcription factors as biomarkers in cancer and other diseases. All the tests in our portfolio detect various characteristic changes that occur from the earliest stages of disease, enabling early detection and potentially a better way to monitor disease progression and a patient’s response to treatment.

Our team has worked tirelessly for more than a decade to evolve and master our understanding of the rich, complex information encoded in circulating chromatin and in particular, in circulating nucleosomes.

We believe that our focus on innovation, robust assay development and a diverse intellectual property portfolio positions us to become a significant player in this cutting-edge field of science.